Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E18.24 EPS (ttm)1.65 Insider Own0.10% Shs Outstand6.39B Perf Week-3.65%
Market Cap192.38B Forward P/E12.91 EPS next Y2.33 Insider Trans7.50% Shs Float6.39B Perf Month-5.76%
Income11.38B PEG8.68 EPS next Q0.56 Inst Own71.60% Short Float0.84% Perf Quarter-2.68%
Sales51.58B P/S3.73 EPS this Y37.50% Inst Trans0.05% Short Ratio1.86 Perf Half Y4.84%
Book/sh11.20 P/B2.69 EPS next Y3.69% ROA23.20% Target Price34.27 Perf Year0.70%
Cash/sh5.07 P/C5.94 EPS next 5Y2.10% ROE52.60% 52W Range26.47 - 32.96 Perf YTD-0.95%
Dividend1.04 P/FCF19.79 EPS past 5Y6.80% ROI10.50% 52W High-8.71% Beta0.76
Dividend %3.46% Quick Ratio2.10 Sales past 5Y1.30% Gross Margin81.90% 52W Low13.65% ATR0.61
Employees77700 Current Ratio2.40 Sales Q/Q-5.60% Oper. Margin33.40% RSI (14)35.48 Volatility2.00% 1.87%
OptionableYes Debt/Eq0.48 EPS Q/Q37.50% Profit Margin80.30% Rel Volume1.03 Prev Close29.89
ShortableYes LT Debt/Eq0.40 EarningsMay 05 BMO Payout16.00% Avg Volume28.72M Price30.09
Recom2.20 SMA20-4.43% SMA50-4.99% SMA2000.37% Volume29,503,800 Change0.67%
02-Jul-13Downgrade Standpoint Research Hold → Sell $24
15-Apr-13Reiterated Barclays Equal Weight $25 → $32
30-Jan-13Reiterated UBS Buy $29 → $31
30-Jan-13Reiterated Argus Buy $28 → $32
22-Jan-13Reiterated Barclays Equal Weight $24 → $25
27-Nov-12Downgrade MKM Partners Buy → Neutral $29 → $25
05-Oct-12Reiterated MKM Partners Buy $27 → $29
01-Nov-11Downgrade Standpoint Research Buy → Hold
07-Oct-11Initiated MKM Partners Buy $20.50
14-Sep-11Downgrade Barclays Capital Overweight → Equal Weight $21 → $19
10-Aug-11Upgrade Argus Hold → Buy $21
05-Aug-11Upgrade Standpoint Research Hold → Buy $21
14-Mar-11Downgrade Standpoint Research Buy → Hold
03-Nov-10Downgrade Argus Buy → Hold
21-May-10Initiated Jefferies Buy $17.80
16-Dec-09Initiated UBS Buy
27-Apr-09Initiated Standpoint Research Buy $20
12-Feb-09Upgrade Leerink Swann Mkt Perform → Outperform
09-Feb-09Upgrade UBS Neutral → Buy
02-Feb-09Upgrade Credit Suisse Neutral → Outperform
16-Apr-14 07:01PM  New kind of trial aims to speed cancer drug development Reuters
06:30PM  The Biggest Biotech Wins of the Week at Motley Fool
02:28PM  Will Recent News Hurt GlaxoSmithKline? at Wall St. Cheat Sheet
01:38PM  Dear Jenny McCarthy, Here's How Many Lives Could Be Saved Cheaply By Making Vaccines More Widely Available at Forbes
12:55PM  Cancer Doctors Plan to Compare Value of Expensive Drugs Bloomberg
12:55PM  Cancer Doctors Plan to Compare Value of Expensive Drugs at Bloomberg
08:25AM  Does Johnson & Johnson Belong in Your Portfolio? at Wall St. Cheat Sheet
15-Apr-14 03:30PM  Portola's Betrixaban Study Design Published Zacks
02:32PM  Does Pfizer Offer Good Value? at Motley Fool
02:05PM  Finding Attractive Yields in Financials, IT and Health Care: A Wall Street Transcript Interview with Kenneth M. Conrad, Ph.D., CFA, a Portfolio Manager at BMO Global Asset Management for the BMO Custom Quantitative Solutions Group Wall Street Transcript
09:04AM  Big Pharma's Turn On RNAi Shows That New Technologies Don't Guarantee R&D Success at Forbes
14-Apr-14 05:58PM  Biotech Tweet of the Week: Love Being Private at Motley Fool
04:08PM  Jefferies Takes J&J, Lilly To Hold; Pfizer Remains Top Pick at Barrons.com
02:00PM  Dow Today: Pfizer (PFE) Lower at TheStreet
10:09AM  Premier Biomedical (BIEI) and the Wild West of Modern Medicine Accesswire
09:05AM  GlycoMimetics presents GMI-1070 data at theflyonthewall.com
07:02AM  AdvilĀ® Relief in Action and Josh Duhamel Celebrate National Volunteer Week with Points of Light & Kick off a Nationwide Relief Tour Business Wire
04:01AM  Pfizer Vs. Eli Lilly, Novartis In Breast Cancer Race at Seeking Alpha
11-Apr-14 04:35PM  Acura Pharma Ends Agreement with Pfizer Zacks
03:07PM  FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon? at TheStreet
02:32PM  Can This Drug Be a Game Changer for Eli Lilly? at Motley Fool
01:11PM  Alzheimers Therapy May Come From New Look at Old Drugs at Bloomberg
10-Apr-14 08:41PM  Zoe's Kitchen IPO priced at $15 per share Reuters
04:22PM  Roche's Competitive Advantage at Seeking Alpha
11:43AM  [video] Pfizer CEO worries about ACA coverage at CNBC
10:02AM  [video] Celgene CEO: Intellectual property is lifeblood of innovation at CNBC
09:31AM  3 Breast Cancer Drugs With Big Potential at Motley Fool
06:51AM  [video] Eli Lilly CEO: We keep investing in R&D at CNBC
09-Apr-14 06:41PM  A Favorable Look at Pfizer and Signet at Barrons.com
05:08PM  Troubled NHLBI TOPCAT Trial Disappoints at Forbes
03:45PM  Teva to Launch Generic Lovaza Zacks
01:00PM  Dow Today: Pfizer (PFE) Lower at TheStreet
11:04AM  "Change the law or stop complaining about it." Hot Stock Minute
07:24AM  Pfizer: It Never Rains, It Pours at Seeking Alpha
08-Apr-14 09:38PM  Big Pharma Opens New Chapter On Big Data Collaboration at Forbes
09:03PM  Why Goldman Sachs and Pfizer Held Back the Dow Tuesday at Motley Fool
07:19PM  Untaxed U.S. corporate profits held overseas top $2.1 trillion: study Reuters
04:49PM  [video] The Crackdown on Counterfeit Drugs at Bloomberg
03:41PM  A Sharp Pullback In Celldex Could Be A Window Of Opportunity at Seeking Alpha
01:05PM  [video] How Many Fake Drugs Are There on the Black Market? at Bloomberg
12:28PM  Study Suggests Link Between Viagra And Melanoma at Forbes
09:40AM  Encouraging Results from Pfizer's Palbociclib Zacks
09:32AM  Pfizer Blockbuster Zyvox Under Attack at Motley Fool
06:41AM  [video] Protecting Viagra: Inside Pfizer's Fake Drug Lab at Bloomberg
07-Apr-14 05:50PM  Balanced Risk-Reward for Pentair Zacks
05:28PM  Pfizer sell-off unwarranted, Barron's says at theflyonthewall.com
04:38PM  Catch Me I'm Falling: Nasdaq's Three-Day Drop Largest Since 2011 at Barrons.com
04:28PM  On The Fly: Closing Wrap at theflyonthewall.com
04:18PM  Stocks fall as tech and momentum names continue to struggle Hot Stock Minute
03:01PM  [$$] Pfizer: Buy the Dip at Barrons.com
02:45PM  Why Pfizer (PFE) Stock Is Down On Monday at TheStreet
02:37PM  Pfizer's Plunge Leads the Dow's Triple-Digit Dive at Motley Fool
02:32PM  Pfizer Inc's Palbociclib Delivers the Goods at Motley Fool
02:02PM  Here's How Intel Corp.'s Executive Bonus Tweaks Help Shareholders Like You and Me at Motley Fool
01:43PM  Why investors should fear the return of the buyback at Fortune
01:04PM  Pfizer shares drop despite positive test for breast-cancer drug at MarketWatch
12:15PM  On The Fly: Midday Wrap at theflyonthewall.com
11:59AM  Boehringer Ingelheim's Oral Anticoagulant Gains New Indication at Forbes
11:23AM  Pfizer Breast-Cancer Drug Scores, But Street Cautious at Investor's Business Daily
11:06AM  Upcoming Data For Athersys Crucial, But Not In Terms Of Immediate Share Price at Seeking Alpha
11:01AM  Dow Drops Despite Intel Upgrade; Pfizer, Visa Drag at Motley Fool
10:20AM  Stocks modestly lower as investors look to quarterly earnings at CNBC
09:53AM  Stocks decline as momentum names continue to fall at CNBC
09:22AM  [$$] Two Drugs Show Promise in Slowing Breast Cancer at The Wall Street Journal
09:18AM  Morning Movers: Tesla Falls on California Credit Reduction; Nasdaq Slap Down Continues at Barrons.com
08:38AM  Should Med School Leaders Serve On Pharma Boards? at Forbes
08:34AM  Does Pfizer Belong in Your Portfolio? at Wall St. Cheat Sheet
07:54AM  [video] Morning Movers: Pfizer Unveils Breast Cancer Drug at Bloomberg
06:15AM  Jobs Rich Irish Mystery Confounds Shrinking Economy Bloomberg
06:15AM  Irish Mystery Confounds as Jobs Rise Amid Shrinking Economy Bloomberg
03:31AM  [$$] Two Drugs Show Promise in Slowing Breast Cancer at The Wall Street Journal
01:24AM  [$$] Two Drugs Show Promise in Slowing Breast Cancer at The Wall Street Journal
01:09AM  [$$] Two Drugs Show Promise in Slowing Breast Cancer at The Wall Street Journal
06-Apr-14 08:13PM  Pfizer Breast Cancer Drug Helps Revive Discarded Strategy Bloomberg
08:13PM  Pfizer Breast Cancer Drug Helps Revive Discarded Strategy at Bloomberg
12:29PM  Pfizer, Lilly Breast Cancer Drugs Slow Tumors in Studies Bloomberg
10:39AM  Pfizer Breast Cancer Drug Results "As Impressive As I've Ever Seen," Researcher Says at Forbes
10:30AM  Pfizers Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer Business Wire
10:30AM  Pfizer, Lilly Breast Cancer Drugs Slow Tumors in Studies at Bloomberg
04-Apr-14 10:28PM  The Biggest Dividends Arent Necessarily the Best at New York Times
06:32PM  What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.? at Motley Fool
04:00PM  Merck KGaA and Auxogyn Collaborate Zacks
03-Apr-14 04:30PM  Stocks Pause Ahead of Big NFP Day at Minyanville
04:10PM  Merck KGaA, Pfizer and Broad Institute Collaborate Zacks
12:21PM  ICON could benefit from ongoing secular shift to outsourcing of clinical trials services Market Realist
11:15AM  PFE May 23rd Options Begin Trading at TheStreet
10:33AM  Will Pfizer Unveil A Breast Cancer Blockbuster This Sunday? at Forbes
09:16AM  Danger Zone: Value Investors at Seeking Alpha
02-Apr-14 06:14PM  Third Consecutive New High for S&P 500; Dow Industrials Not Quite Positive in 2014 at Barrons.com
02:31PM  Biggest Clinical Wins of the Week: Large-Cap Edition at Motley Fool
02:09PM  Obscured Information Complicates Value Investing at Forbes
11:55AM  Uniqure rises after Baxter acquires Chatham Therapeutics at theflyonthewall.com
10:06AM  Partnership Targets $240 Million at Neglected Tropical Diseases at The Wall Street Journal
01-Apr-14 06:31PM  A New Frontier for Biogen Idec, Inc.? at Motley Fool
05:31PM  Biotech Auxilium Boosts Position In Men's Health Care at Investor's Business Daily
05:17PM  Health leaders on drug co. boards; a conflict? AP
05:01PM  Hobby Lobby Invested In Numerous Abortion And Contraception Products While Claiming Religious Objection at Forbes
05:01PM  Hobby Lobby 401(k) Discovered To Be Investor In Numerous Abortion And Contraception Products While Claiming Religious Objection! at Forbes
03:30PM  Update on Pfizer's OTC Nexium 24HR Zacks
03:08PM  [video] Jim Cramer Says Watch Celgene, Salesforce.com for Growth in Q2 at TheStreet
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. The company's Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. The company's Established Products and Emerging Markets segment offers prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions, as well as sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. Its Consumer Healthcare segment provides non-prescription products in a range of therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company primarily offers biopharmaceutical products, including Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and grocery and convenience stores. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
YOUNG JOHN DGroup PresidentMar 17Sale31.389,000282,42099,647Mar 18 09:33 AM
PFIZER INC10% OwnerMar 12Buy11.00272,7272,999,9971,235,330Mar 14 03:27 PM
SUSMAN SALLYExecutive Vice PresidentMar 04Sale32.5967,5852,202,872173,637Mar 05 05:36 PM
Dolsten MikaelPresident R&DMar 04Sale32.5835,7891,165,929344,571Mar 05 05:36 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerMar 04Sale32.555,082165,419171,756Mar 05 05:37 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerMar 03Option Exercise26.2075,5001,978,100274,699Mar 05 05:37 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerMar 03Sale32.0297,8613,133,674176,838Mar 05 05:37 PM
READ IAN CChairman & CEOFeb 26Option Exercise12.70324,9324,126,6361,410,536Feb 28 04:52 PM
SUSMAN SALLYExecutive Vice PresidentFeb 26Option Exercise12.70130,8751,662,113312,499Feb 28 04:52 PM
YOUNG JOHN DGroup PresidentFeb 26Option Exercise12.7057,586731,342116,884Feb 28 04:52 PM
BOURLA ALBERTGroup PresidentFeb 26Option Exercise12.7021,482272,82192,447Feb 28 04:52 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 26Option Exercise12.7056,411716,420228,878Feb 28 04:52 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 26Option Exercise12.70324,9324,126,636615,673Feb 28 04:52 PM
HILL CHARLES HExecutive Vice PresidentFeb 26Option Exercise12.7034,731441,084104,046Feb 28 04:52 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 26Option Exercise12.7034,568439,014120,562Feb 28 04:52 PM
JOHNSON RADY AExecutive Vice PresidentFeb 26Option Exercise12.7029,695377,12740,480Feb 28 04:52 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 26Option Exercise12.7029,695377,12783,716Feb 28 04:52 PM
OLSON LAURIE JExecutive Vice PresidentFeb 26Option Exercise12.7031,772403,50468,167Feb 28 04:52 PM
PFIZER INC10% OwnerFeb 04Buy8.00227,2611,818,0881,794,803Feb 06 03:53 PM
DAMELIO FRANK AExecutive Vice PresidentJan 13Sale30.82131,8104,062,225356,451Jan 14 07:13 PM
DAMELIO FRANK AExecutive Vice PresidentJan 13Sale30.8628,190869,817328,261Jan 14 07:13 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 14Option Exercise26.2092,0002,410,400152,447Nov 18 03:31 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 14Sale32.1092,0002,953,06360,447Nov 18 03:31 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerNov 01Sale31.2010,000311,985174,841Nov 04 03:59 PM
READ IAN CChairman & CEOOct 28Option Exercise26.20338,0008,855,6001,412,267Oct 29 05:44 PM
READ IAN CChairman & CEOOct 28Sale30.57338,00010,331,3151,074,267Oct 29 05:44 PM
LANKLER DOUGLAS MExecutive Vice PresidentSep 16Option Exercise26.0660,9001,587,198150,617Sep 18 04:27 PM
LANKLER DOUGLAS MExecutive Vice PresidentSep 16Sale28.7060,9001,748,02589,717Sep 18 04:27 PM
Lewis-Hall Freda CExecutive Vice PresidentSep 16Sale28.7038,4611,103,831118,383Sep 18 04:20 PM
CORNWELL W DONDirectorAug 12Buy29.0975822,0502,217Aug 13 03:58 PM
CORNWELL W DONDirectorAug 12Sale29.0975822,0501,459Aug 13 03:58 PM
HILL CHARLES HExecutive Vice PresidentJul 31Option Exercise26.0496,5002,512,460171,362Aug 01 05:39 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerJul 31Sale29.6314,688435,180183,703Aug 01 05:39 PM
HILL CHARLES HExecutive Vice PresidentJul 31Sale29.6496,5002,860,43474,862Aug 01 05:39 PM
SCHULMAN AMY WExecutive Vice PresidentMay 15Sale29.3670,0002,055,389223,497May 16 08:18 PM
READ IAN CChairman & CEOMay 15Sale29.3969,9002,054,3351,061,463May 16 08:10 PM
DAMELIO FRANK AExecutive Vice PresidentMay 15Sale29.33100,0002,932,863485,682May 16 07:24 PM